Targeting Myelomonocytic Cells to Revert Inflammation-Dependent Cancer Promotion
Open Access
- 15 October 2005
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (20), 9113-9116
- https://doi.org/10.1158/0008-5472.can-05-2714
Abstract
Tumor development and progression are strongly linked to inflammation and the presence of tumor-associated macrophages (TAMs). In murine tumors, antitumor activity can be achieved by targeting TAM recruitment, survival, activation, polarization, effector signaling, or extracellular matrix interactions. Thus, it may be possible to increase the efficacy of conventional cancer therapeutic strategies by targeting TAMs.Keywords
This publication has 22 references indexed in Scilit:
- Inflammation by remote controlNature, 2005
- Endogenous Inhibitors of AngiogenesisCancer Research, 2005
- De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependentCancer Cell, 2005
- Anti-inflammatory Properties of the Novel Antitumor Agent Yondelis (Trabectedin): Inhibition of Macrophage Differentiation and Cytokine ProductionCancer Research, 2005
- Smoldering and polarized inflammation in the initiation and promotion of malignant diseaseCancer Cell, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- NF-κB functions as a tumour promoter in inflammation-associated cancerNature, 2004
- Tumour-educated macrophages promote tumour progression and metastasisNature Reviews Cancer, 2004
- Leukocyte, Rather than Tumor-produced SPARC, Determines Stroma and Collagen Type IV Deposition in Mammary CarcinomaThe Journal of Experimental Medicine, 2003
- Inflammation and cancerNature, 2002